MAJOR DEVELOPMENT by the company. Hopefully. the first of many new Markets being served by MPXI
"MPX International Corp. has completed its first delivery of cannabis flower pursuant to its production and distribution agreement with Panaxia Pharmaceutical Industries Israel Ltd., the largest manufacturer and distributor of medical cannabis products in Israel, for the packaging and distribution of cannabis which will be marketed and sold in Israel under Canveda's medical brand Salus BioPharma.
"MPXI has a long-standing relationship with Panaxia and welcomes the opportunity to market our brand in Israel as part of our international cannabis strategy," noted W. Scott Boyes, chairman, president and chief executive officer of MPX International. "Panaxia is a major player in the Israeli market and an emerging participant in the global cannabis space and we are honoured to be able to work with the Panaxia team on this and potentially other projects."
A first shipment of 100 kilograms of high-quality cannabis flower was shipped from Canada to Israel on Nov. 15 after receiving an export permit from Health Canada.
Panaxia uses high-quality cannabis flower to manufacture and distribute a variety of standardized, pharma-grade, smokeless, measured-dosage cannabinoid-based products, including sublingual tablets, slow release tablets, pastilles, rectal suppositories, vaginal suppositories, skin-care ointments, topical patches and oral spray inhalers.
The Salus BioPharma products will be sold to patients with a variety of conditions such as PTSD, chronic pain, cancer, epilepsy, Parkinson's, Alzheimer's, anorexia and HIV/AIDS.
"We are proud to be collaborating on this project with our Canadian partners, MPX International Corp. and expand our cooperation in Israel and potentially other international markets. As an experienced pharmaceutical company and the largest manufacturer and distributor of medical cannabis products in Israel, we are committed to providing premium, standardized and scientifically backed pharmaceutical cannabis products to our partners and patients worldwide. MPXI leads the pharmaceutical approach to medical cannabis in Canada, which makes them a natural partner for distribution of high-quality pharmaceutical cannabis products in Israel," said Assi Rotbart, general manager of Panaxia.
"We have delivered our initial 100 kg of bulk high-quality sativa and indica cannabis strains as an initial foray into the Israeli market. Panaxia will be responsible for quality control, packaging and distribution of Salus BioPharma products in Israel," said Michael Arnkvarn, chief operating officer, Canada, of MPXI. "The Salus BioPharma brand is our premier medical brand and we are excited to commence international distribution of our Salus BioPharma products with Panaxia in Israel.
Following this initial foray into the international cannabis market, we are working to expand distribution of the Salus BioPharma Brand to additional international markets. We are now in the process of securing import and export permits for an additional 200 kg shipment in January of 2021."